Search results
Should We Be Delighted With GSK plc's (LON:GSK) ROE Of 36%?
Simply Wall St. via Yahoo Finance UK· 2 days agoWhile some investors are already well versed in financial metrics (hat tip), this article is for...
Will GSK Stock Rebound To Its 2022 Highs Of $47?
Forbes· 1 day agoGSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022.
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Zacks via Yahoo Finance UK· 2 days agoGSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration...
GSK to Pay CureVac Up to €1.4 Billion for Flu, Covid Shots
Bloomberg· 3 days agoHave a confidential tip for our reporters? GSK Plc agreed to pay as much as €1.4 billion ($1.5...
GSK takes full control of flu vaccine programme in €1.45bn deal
Proactive Financial News· 3 days agoGSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new...
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Zacks via Yahoo Finance UK· 2 days agoIt was a regular week for the biotech sector with quite a few important pipeline and regulatory...
GSK and CureVac to Restructure Collaboration into New Licensing Agreement (1)
PharmiWeb· 3 days agoLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today ...
GSK buys full rights to make COVID, influenza vaccines from CureVac
Reuters· 3 days agoGSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine...
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
Zacks via Yahoo Finance UK· 5 days agoModerna’s stock also took a hit last week after it presented new data on mResvia to the CDC, which...
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge
Reuters· 5 days ago, opens new tab and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming...